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Background: Insufficient arterial blood flow is the one cause of flap necrosis. Cilostazol is an inhibitor of
phosphodiesterase III and increases cyclic AMP level in vascular smooth muscle cell causing vasodilation. Therefore,
effect of cilostazol is expected to improve the viability of the flap.
Methods: Double blinded randomized controlled trial was conducted. The study was to compare the survival of
dorsal rat flaps between preoperative cilostazol supplemented diet and regular diet. The flap survival area was
measured using PixArea Image software on post operative day 1,3,5 and 7. Fluorescein injection was performed to
evaluate the exactly area of flap survival on postoperative day 7 and morphology of arterioles and venules were
examined by histopathologic examination.
Results: A statistical significance was found in the percentage of area of flap survival between cilostazol
supplemented diet and control group on postoperative day 3, 5 and 7 (p < 0.05). Fluorescein injection showed the
higher area of flap survival in cilostazol group than the control group (p < 0.05). Histopathologic examination
showed dilation of vessels in the cilostazol group.
Conclusion: Preoperative cilostazol in rats can enhance skin flap survival.
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Reconstruction of tissue defect by flap coverage is widely
used in the field of plastic surgery. Despite more under-
standing of the mechanism of flap necrosis and the
advances in surgical technique, necrosis of flap remains
a significant problem surgery. Flap necrosis is demon-
strated by insufficient arterial flow, inadequate venous
drainage or combination of both [1,2]. Many techniques
have been introduced to alleviate this problem. Delay flap
procedure increase the viability, however, disadvantage
of this technique is requiring second operations [3-7].
Many pharmacological agents [8] have been introduced to* Correspondence: pataranat@hotmail.com
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unless otherwise stated.improved ischemia of flap in experimental studies, how-
ever, clinical outcome are still controversial. These agents in-
clude sympatholytics, vasodilators, calcium channel blockers,
anticoagulants [9,10], volume expander agent [11], prosta-
glandin inhibitors [12], and botulinum toxin A [13,14].
Cilostazol is a selective inhibitor of phosphodiesterase
type III, by which it increases intracellular cyclic AMP
(cAMP) and also raises the vascular smooth muscle cell’s
cAMP level causing vasodilation. It is an antithrombotic
that also reversibly inhibits platelet aggregation and
causes arterial vasodilation. Cilostazol was approved for
use in England by the National Institute for Clinical
Excellence (NICE) and has been licensed in the United
States since 1999, by the Food and Drug Administration
(FDA). It is benefit to treat patients suffering from inter-
mittent claudication without rest pain and no peripheral
tissue necrosis as it improves pain-free walking distancesral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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smooth muscle cell that causing vasodilation is expected to
increase the survival of flap. However, the effect of cilosta-
zol on the skin flap survival has not been established.
Authors have hypothesized that pre-operative adminis-
tration of cilostazol will be improved the viability of the
flap. The objective is to study the efficacy of pre-
operative administration of cilostazol in survival of ran-
dom cutaneous flap in rat model.
Methods
This study was approved by the Animal Care Commit-
tee of Phramongkutklao Hospital and Ethic Committee.
Thirty male Sprague–Dawley rats weighing between
250 and 350 gm were used in this study and cared for
under the National Research Council’s guidelines for
the care and use of laboratory animals. The rats were
housed in a temperature-controlled room (25 ± 2°C) on
a 12 hours light: 12 hours dark cycle with free access to
food and water.
Rats were randomly divided by the first surgeon into
two groups (15 rats in each group). First group was
given with cilostazol supplemented diet (cilostazol
group) (40 mg/kg/day) every day for 7 days and the sec-
ond group was the control group (regular diet). Body
weight was not significantly different among groups dur-
ing the experiment. All rats were performed under gen-
eral anesthesia induced by intraperitoneal injections of a
xylazine 2–4 mg/kg and zolitil 30 – 40 mg/kg mixtured
by second surgeon (blinded about the rat groups). Fol-
lowing induction of general anesthesia, the skin of the
dorsal trunk was shaved and then prepared with Beta-
dine solution, and rats were placed in a prone position.
A 2X8 cm2 cephalic based rectangular dorsal cutaneousFigure 1 A 2X8 cm2 cephalic based rectangular dorsal skin flap was designflap was designed and elevated with base of flap at the
lower margin of the scapula (Figure 1). A silicone sheath
was placed under the flap to block the new blood supply
from the bed, then the flap was returned to its original
position and carefully sutured into place using 4/0 Nylon
suture. The rats were returned to individual cages.
Flap survival was checked on postoperative day 1, 3, 5
and 7 by second surgeon. Betadine solution was
cleaned on the flap by normal saline solution before
taking a photograph. A digital photograph was taken
30 cm. from the rats and the PixArea Image Program
(version 1.03 (2008) software, Finland was used. Using
the program, the length of the image was converted
to the actual length, and the surface area of flap sur-
vival was calculated. Discoloration of the flap and dry
eschar formation were regarded as gross criteria of ne-
crosis. Flap survival area was calculated by the percent-
age of viable surface to the total surface area by the
second surgeon.
Fluorescein testing
Fluorescein testing was performed to demonstrate the
exactly survival area of the flap. Seventh day after the
flap elevation, all rats were reanesthetized and 0.3 ml
of 10% sodium fluorescein was administrated intraven-
ous. Twenty minutes after the fluorescein injection, per-
fusion at the inner surface of flap was demonstrated
under a Blacklight lamp in a darkened room. A digital
photograph was taken 30 cm. from the rats. The sur-
vival area was defined by demonstration of the fluores-
cein appearance. The flap survival was calculated by the
percentage of viable surface to the total surface area by
the second surgeon and compared between groups by
the first surgeon.ed on the rats and then elevated.
Table 1 Mean and standard deviation of the percentage of flap survival in each group
Day Cilostazol (n = 15) Control (n = 15) p-value
Mean(%) (min-max) Standard deviation Mean(%) (min-max) Standard deviation
1 94.26 (89.01-100.00) 4.03 91.17 (85.34-100.00) 4.25 0.064
3 80.30 (70.65-85.67) 4.39 75.41 (69.98-81.67) 4.51 <0.05
5 52.69 (42.81-61.45) 4.87 42.90 (35.80-48.58) 3.72 <0.05
7 49.76 (40.89-58.67) 4.35 40.08 (32.78-45.67) 4.07 <0.05
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Tissue samples were taken at 1 and 4 cm. from the
base of flap and preserved in 10% formalin solution.
Sampling tissues were embedded in paraffin blocks and
stained with haematoxylin and eosin for histopatho-
logical examination.
Statistical analysis
The difference in the mean area of survival and mean per-
centage of flap survival between the two individual groupsFigure 2 Comparison of flaps between cilostazol group (above) and contrwere analyzed using the Mann–Whitney U-test. Probabil-
ities of less than 0.05 were accepted as statistical significant.
Results
Infection and mortality were not observed during this
study. Partial flap necrosis was observed on the distal
part of the flap on day1,3,5 and 7 after flap elevation
(Table 1) (Figure 2). The mean of flap survival on post-
operative day 1 in the cilostazol group was 94.26%
and in the control group was 91.17%. No statisticalol group (below) on postoperative day 1, 3, 5 and 7.
Figure 3 Fluorescein injection showed the higher area of flap survival in cilostazol group (left) than control group (right).
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The mean areas of flap survival in the cilostazol group
were 80.3%, 52.69% and 49.76%, respectively and higher
than the control group (75.41%, 42.9% and 40.08%) on
post operative day 3, 5 and 7. The results between the
groups administrated with pre-operative cilostazol and
the control group were statistical significant on day 3, 5
and 7(p < 0.05). Fluorescein injection showed the higher
area of flap survival in cilostazol group than control
group (Figure 3). Statistical significance was found be-
tween cilostazol and control group when evaluation was
performed by fluorescein injection (p < 0.05) (Table 2).
No statistical significance was found between fluores-
cein injection and visual assessment on postoperative
day 7. Histopathologic evaluation on postoperative dayTable 2 The mean of the percentage of flap survival in
each group, evaluation by fluorescein injection on
postoperative day 7





Fluorescein injection 50.57 (41.56-60.12) 40.87 (33.77-46.35) <0.05
Visual assessment 49.76 (40.89-58.67) 40.08 (32.78-45.67) <0.057 showed dilatation of arterioles and venules in the
cilostazol group. Compare with the control group, his-
topathologic examination showed a collapsed morph-
ology of vessels (Figure 4).
Discussion
Flap necrosis remains a significant problem in surgery.
Flap necrosis is a result of simply inadequate end flow
due to either vasoconstriction of the small arterioles or
perfusion pressure decrease at a distance from the ped-
icle vessels. A random skin flap receives blood supply,
mainly from subdermal plexus and distinguished from the
axial flap that contains a dominant vessel inside. A ran-
dom skin flap can be used without any specific problem as
long as the ratio of length to width is around 1.5 – 2: 1
but if the ratio is higher, complications such as skin necro-
sis may occur when the flap is elevated [17].
Cilostazol is an inhibitor of phosphodiesterase type
III, increases cyclic AMP (cAMP) in platelets and raises
the vascular smooth muscle cell’s cAMP level causing
arterial vasodilation. As an antithrombotic, it also revers-
ibly inhibits platelet aggregation. Cilostazol has better
properties than salicylic acid, such as a rapid onset
(4 hours) and rapid cessation of the effect (within 48 hours)
[18]. Although, side effects are diarrhea, headache, dizziness
Figure 4 Histopathologic examination of the flap in cilostazol group (above) showed dilation of arterioles and venules. Compare with the control
group (below), histopathologic examination showed a collapsed morphology of vessels (H&E stain X 100).
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ure, it is used to treat patients suffering from intermittent
claudication without rest pain and no peripheral tissue ne-
crosis as it improves pain-free walking distances [15,16].
Kim SH et al. [19] reported that cilostazol plus aspirin
taken orally effectively increased the flow volume in a
thrombotic anastomosis model in a rat. Yuzawa I [20]
reported that oral administration of cilostazol can be
used to decrease ischemic stroke. Nakamura et al. [21]
reported that cilostazol induces vasodilation of the rat
thoracic aorta and this effect was dependent on the
endothelium, which released nitric oxide (NO) from aor-
tic endothelial cell. Nitric oxide is an important role in
flap physiology after flap elevation and final mediator to
affect vascular smooth muscle causing arterial vasodila-
tion. Many studies reported effect of cilostazol on nitric
oxide production and showed that cilostazol potentiates
interleukin-1 –beta (IL-1beta) induced NO production,
at least partially through a cAMP-dependent pathway[22,23]. The cilostazol also might attenuate cytokine –
induced expression of the inducible NO synthase protein
expression(iNOS) and increase in the accumulation of
nitrite, a stable met abolite of NO [23,24]. Some studies
showed the advantage of locally application of cilostazol
that inhibits neointimal hyperplasia of vein graft in rat
model [25], increase blood flow in rabbit skin [26].Most
of the previous studies reported the effect of cilostazol
to improve blood flow, however, the effect of cilostazol
on skin flap survival has not been established. In this
study, cilostazol was used as a pharmacologic adjuvant
therapy and the mechanism is considered to increase the
survival of the flap. It is hypothesized that cilostazol may
cause mainly on vascular smooth muscle and causing
vasodilation, increasing blood volume to the flap either
cAMP dependent pathway or NO production by in-
crease iNOS and IL-1beta. A 2X8 cm2 cephalic based
dorsal rat flap was advocated by McFarlane et al. in 1965
[27]. They originally described the dorsal skin flap of the
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the authors used pre-operative at a dose of 40 mg/kg
according to Nakamura et al. [21]. They reported that
the serum concentration of cilostazol (40 mg/kg) in rats
was about 1.5 ug/ml, equivalent to those of patients
treated with cilostazol.
No statistical significance was found between each
group on post operative day 1, maybe the area of flap
necrosis on first day after the operation was difficult to
determine. However, three days after operation, the de-
marcations of necrosis are well defined. Percentage of
flap survival was statistical significant higher in cilostazol
group than control group and confirmation of flap
survival was performed by fluorescein injection and his-
topathologic evaluation.
Rat’s skin is different from human’s skin, especially, skin
of rat has layer of panniculus carusus muscle. Therefore, a
direct comparison between random skin flap of rat and
human is difficult. Furthermore, the number of rats in
each group was small, so further experiments in human
with more subjects are needed.
Conclusion
Pre-operative administration of cilostazol has significantly
increased flap survival of a dorsal rat flap compared with
the control group on post operative day 3,5 and 7. Herein,
we hoped that this study will result in better treatments
and result guidelines to be benefit of patients in the future.
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